“Real-World” Breo Study: A Q&A With GSK’s David Leather
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline is evaluating its once-daily ICS/LABA Breo Ellipta in a “real-world” trial called the Salford Lung Study, with as little intervention from the clinical trial team as possible, to see how the product impacts health outcomes versus existing treatments. David Leather, MD, global medical affairs leader for GSK’s respiratory franchise, is heading the trial and talks about the trial design, challenges, and why the company launched the study in the first place.
You may also be interested in...
Breo Ellipta is associated with a lower rate of exacerbations in real world Salford study, but some analysts question whether it's too late to turn performance around in a highly competitive, highly price-conscious market.
The UK pharma had pinned much of its long-term hopes for Breo on successful results of SUMMIT, which compared the morbidity and mortality of COPD patients at increased risk of cardiovascular disease taking Breo versus placebo.
Massive collections of clinical data can now be analyzed in seconds rather than in days, and could help in recruiting patients into clinical studies, but the randomized clinical trial is likely to remain the favored way of finding answers to clinical questions.